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Abstract
Background:  Helicobacter  pylori  (H.  pylori)  is  the  main  risk  factor  for  the  development  of
chronic gastritis,  gastric  ulcer,  and  gastric  cancer.  In  H.  pylori-infected  individuals,  the  clinical
result is  dependent  on  various  factors,  among  which  are  bacterial  components,  the  immune
response,  and  environmental  inﬂuence.
Aims:  To  compare  IFN-  expression  with  the  H.  pylori  vacA  and  cagA  genotypes  in  patients  with
chronic gastritis  and  patients  with  gastric  cancer.
Methods:  Ninety-ﬁve  patients  diagnosed  with  chronic  gastritis  and  20  with  gastric  cancer  were
included  in  the  study.  Three  gastric  biopsies  were  taken;  one  was  used  for  the  molecular  detec-
tion and  genotyping  of  H.  pylori;  another  was  ﬁxed  in  absolute  alcohol  and  histologic  sections
were made  for  determining  IFN-  expression  through  immunohistochemistry.
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Results:  No  differences  were  found  in  the  cells  that  expressed  IFN-  between  the  patients  with
chronic gastritis  (median  percentage  of  positive  cells:  82.6%  in  patients  without  H.  pylori  and
82% in  infected  persons)  and  those  with  gastric  cancer  (70.5%  in  H.  pylori-negative  patients  and
78.5% in  infected  persons).  IFN-  expression  was  69%  in  chronic  gastritis  patients  infected  with
H. pylori  vacAs2m2/cagA− it  was  86.5%  in  patients  infected  with  H.  pylori  vacAs1m2/cagA-,
86.5% in  vacAs1m1/cagA−,  and  82%  in  vacAs1m1/cagA+.  Similar  data  were  found  in  the  patients
with gastric  cancer.
Conclusions:  IFN-  expression  varied  depending  on  the  H.  pylori  vacA  and  cagA  genotype,  but
not in  accordance  with  the  presence  of  chronic  gastritis  or  gastric  cancer.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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Diversidad  de  los  genotipos  vacA  y  cagA  de  Helicobacter  pylori  y expresión
de  interferón  gamma  en  pacientes  con  gastritis  crónica  y  cáncer  gástrico
Resumen
Antecedentes:  El  H.  pylori  es  el  principal  factor  de  riesgo  para  el  desarrollo  de  gastritis  crónica,
úlcera gástrica  y  cáncer  gástrico.  El  resultado  clínico  en  infectados  por  esta  bacteria  depende
de varios  factores,  entre  ellos  los  componentes  bacterianos,  la  respuesta  inmune,  y  la  inﬂuencia
del medio  ambiente.
Objetivo:  Comparar  la  expresión  de  IFN-  con  los  genotipos  vacA  y  cagA  de  H.  pylori  en
pacientes con  gastritis  crónica  y  cáncer  gástrico.
Pacientes  y  métodos:  Se  incluyeron  95  pacientes  con  diagnóstico  de  gastritis  crónica  y  20  con
cáncer gástrico.  Se  tomaron  3  biopsias  gástricas,  una  se  utilizó  para  la  identiﬁcación  molecular  y
genotipiﬁcación  de  H.  pylori.  Otra  fue  ﬁjada  en  alcohol  absoluto  y  realizaron  cortes  histológicos
para determinar  la  expresión  de  IFN-  por  inmunohistoquímica.
Resultados:  No  se  encontraron  diferencias  en  las  células  que  expresaron  IFN-  entre  pacientes
con gastritis  crónica  (mediana  del  porcentaje  de  células  positivas:  82.6%  en  pacientes  sin
H. pylori  y  82%  en  personas  infectadas)  y  cáncer  gástrico  (70.5%  en  pacientes  H.  pylori-
negativos  y  78.5%  en  infectados).  En  pacientes  con  gastritis  crónica  infectados  por  H.  pylori
vacAs2m2/cagA− la  expresión  de  IFN-  fue  del  69%,  en  pacientes  con  H.  pylori  vacAs1m2/cagA−
fue  de  86.5%,  en  vacAs1m1/cagA− del  86.5%,  y  en  vacAs1m1/cagA+ del  82%.  En  cáncer  se
encontraron  datos  similares.
Conclusión:  La  expresión  de  INF-  varía  dependiendo  del  genotipo  vacA  y  cagA  de  H.  pylori,
pero no  de  acuerdo  a  la  presencia  de  gastritis  crónica  o  cáncer  gástrico.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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Almost  half  the  worldwide  population  is  infected  with  Heli-
cobacter  pylori  (H.  pylori) and  it  is  the  main  cause  of
chronic  gastritis,  gastric  or  duodenal  ulcer,  gastric  cancer,
and  mucosa-associated  lymphoid  tissue  (MALT)  lymphoma,
also  known  as  extranodal  marginal  zone  B  cell  lymphoma.1-3
The  cytotoxin-associated  gene  A  (CagA)  and  the  vacuolat-
ing  cytotoxin  (VacA)  are  H.  pylori  virulence  factors  that  have
multiple  effects  on  the  human  epithelial  cell.4 CagA-positive
H.  pylori  strains  are  associated  with  more  severe  inﬂam-
mation  than  the  cagA-negative  strains.  H.  pylori  transfers
the  CagA  protein  and  other  soluble  factors  to  the  cytoplasm
of  the  epithelial  cell  through  its  type  IV  secretion  system.5
CagA  activates  intracellular  signaling  pathways  that  lead  to
the  activation  of  transcription  factors  that  modulate  proin-
ﬂammatory  cytokine  expression,  to  immune  cell  inﬁltration,
to  cell-to-cell  adhesion  damage,  and  to  change  in  epithelial
m
t
oell  polarity  and  permeability.3 The  VacA  toxin  induces  vac-
olation,  apoptosis,  and  inhibition  of  cell  proliferation.3,6 All
he  H.  pylori  strains  contain  the  vacA  gene,  which  is  poly-
orphic  in  the  signal  (s1a,  s1b,  s1c,  and  s2  alleles)  and  mid
m1  and  m2  alleles)  regions.  Each  vacA  gene  contains  an
 allele  and  an  m  allele  and  the  diversity  in  the  sequence
ffects  the  vacuolating  activity  of  the  cytotoxin.  The  vacA
1m1  strains  are  associated  with  more  severe  disease.4,7
H.  pylori  induces  a  strong  immunologic,  humoral,  and
ellular  response,  characterized  by  the  inﬁltration  of  neu-
rophils,  macrophages,  eosinophils,  and  lymphocytes  into
he  infection  site.  Leukocyte  migration  is  mediated  by
ytokines  and  chemokines  released  by  the  epithelial  and
mmune  cells.  However,  despite  the  high  number  of  inﬁl-
rating  leukocytes,  the  bacterium  is  not  eliminated  in  the
ajority  of  the  infected  subjects,  and  the  intensity  of
he  inﬂammatory  response  contributes  to  the  clinical  result
f  the  infection.8-9 In  the  gastric  mucosa  of  adults  with
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control.  Sterile  deionized  water  was  used  instead  of  DNA  for
the  negative  control.  All  the  reactions  were  made  in  a  ther-
mal  cycler  Mastercycler  Ep  gradient  (Eppendorf,  Hamburg,
Germany).
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Figure  1  Genotyping  of  H.  pylori.  Lane  1:  1  kb  plus
molecular  weight  marker;  lane  2:  negative  control;  lane
3: positive  control,  DNA  from  the  H.  pylori  strain  J99,
vacAs1m1/cagA+/babA2+ genotype;  lanes  4,  7,  and  9:  clinical
samples  of  vacAs2m2/cagA−/babA2− genotype;  lane  5:  clinical22  
astritis  or  peptic  ulcer  that  are  infected  with  H.  pylori,
here  is  a  predominant  Th1-type  immune  response,  with  a
igh  level  of  expression  of  interferon  gamma  (IFN-) and
nterleukin-2  (IL-2)  and  a  low  level  of  expression  of  IL-4  and
L-10.9
IFN- is  an  important  mediator  of  innate  and  adaptive
mmunity.  It  is  produced  mainly  by  T  CD4+ and  CD8+ cells  and
y  natural  killer  (NK)  cells.  This  cytokine  is  overexpressed  in
he  stomach  of  humans  and  mice  infected  with  Helicobacter
pp.10 IFN- plays  a  dual  role  in  response  to  H.  pylori  infec-
ion;  on  the  one  hand,  it  induces  gastric  inﬂammation  and
romotes  the  appearance  of  pre-neoplastic  lesions  caused
y  the  infection,  and  on  the  other,  IFN- reduces  bacte-
ial  colonization  and  is  essential  for  the  elimination  of  the
nfection.11-12
Previous  studies  found  that  IFN- levels  were  higher
n  patients  infected  with  H.  pylori  than  in  uninfected
atients.9,13-15 In  2007,  Wang  et  al.  found  that  in  patients
nfected  with  cagA+ H.  pylori, the  cellular  immune  response
ediated  by  Th1  cells  was  associated  with  earlier  stages  of
astric  carcinogenesis,  whereas  humoral  immunity  mediated
y  Th2  cells  predominated  in  the  advanced  stages.16 Despite
he  fact  that  increased  IFN- expression  has  been  observed
n  the  gastric  mucosa  of  H.  pylori-positive  patients,  whether
r  not  the  expression  of  this  cytokine  varies  with  the  vacA
nd  cagA  genotypes  of  the  bacterium  has  not  been  studied.
o  the  best  of  our  knowledge,  no  data  have  been  published
ocumenting  IFN- expression  in  Mexican  patients  with  gas-
ric  diseases  associated  with  H.  pylori  infection.  The  aim
f  this  study  was  to  relate  IFN- expression  with  H.  pylori
nfection  and  with  the  vacA  genotypes  and  cagA  status  of
he  bacterium  in  patients  with  chronic  gastritis  and  patients
ith  cancer.
ethods
atients
atients  that  underwent  an  upper  gastrointestinal  endo-
copy  at  the  Hospital  General  «Raymundo  Abarca  Alarcón»
nd  the  Unidad  Especializada  en  Gastroenterología  Endo-
copía  in  the  city  of  Chilpancingo  and  the  Endoscopy  Service
f  the  Instituto  Estatal  de  Cancerología  «Arturo  Beltrán
rtega» in  Acapulco,  Guerrero,  Mexico,  within  the  time
rame  of  August  2011  and  March  2013  were  included  in
he  study.  The  selected  patients  had  undergone  no  H.
ylori  eradication  treatment  during  the  month  prior  to  the
ndoscopic  procedure.  Patients  with  immunosuppressant  or
onsteroidal  anti-inﬂammatory  treatment  were  excluded
rom  the  study.  The  patients  or  their  parents  signed  state-
ents  of  informed  consent.  A  questionnaire  was  applied
o  the  patients  that  agreed  to  participate  in  the  study  in
rder  to  record  general  data  and  information  related  to  the
isease.  The  project  was  approved  by  the  Bioethics  Com-
ittee  of  the  Universidad  Autónoma  de  Guerrero  and  the
articipating  hospitals.ndoscopy  and  biopsy  collection
he  endoscopy  was  performed  with  a  video  processor  and
ideo  gastroscope  (Fujinon,  Wayne,  NJ,  USA),  after  a  night
s
s
s
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f  fasting.  In  each  patient,  three  gastric  biopsies  were  taken
rom  the  antrum,  body,  or  the  tumor;  one  was  placed  in  a
uffering  solution  (Tris  10  mM  pH  8.0,  EDTA  20  mM  pH  8.0,
DS  0.5%)  for  the  molecular  diagnosis  of  H.  pylori. Another
as  ﬁxed  in  absolute  alcohol  to  verify  IFN- expression
hrough  immunohistochemistry.  The  last  biopsy  was  ﬁxed  in
uffered  formalin  for  the  histopathologic  study.  The  histo-
ogic  slices  were  stained  with  hematoxylin  and  eosin  and
valuated  by  a  pathologist  using  the  updated  Sydney  system
riteria17 or  the  Lauren  classiﬁcation.18
elicobacter  pylori  detection  and  genotyping
otal  DNA  was  extracted  from  the  gastric  biopsies  using
he  phenol-chloroform-isoamyl  alcohol  technique  after  pro-
einase  K  digestion.19 H.  pylori  detection  was  carried
ut  through  PCR,  amplifying  a  fragment  of  the  16S  rRNA
ene,  following  the  methodology  previously  described  by
artínez-Carrillo  et  al.20 The  H.  pylori-positive  samples
nderwent  a  second  PCR  with  starters  for  amplifying  the
 and  m  region  of  the  vacA  gene,21-22 the  cagA  gene,23 and
he  babA2  gene.24 The  following  were  mixed  in  a  ﬁnal  vol-
me  of  25  L:  500  ng  of  DNA,  1.5  mM  of  MgCl2,  0.15  mM  of
NTPs  (Invitrogen,  Carlsbad,  CA,  USA),  1.3  U  of  Platinum®
aq  DNA  polymerase  (Invitrogen,  Carlsbad,  CA,  USA),  and
he  required  oligonucleotide  concentrations  of  2.5  pM  for
acA,  5  pM  for  cagA, and  12.5  pM  for  babA2. The  ampliﬁ-
ation  program  included  an  initial  denaturalization  step  at
4 ◦C  for  10  min,  35  cycles  at  94 ◦C  for  1  min,  57 ◦C  for  1  min,
2 ◦C  for  1  min,  and  a  ﬁnal  extension  step  at  72 ◦C  for  10  min
ﬁgure  1).  In  each  PCR,  DNA  from  the  J99  strain  was  used,
ith  the  vacAs1m1/cagA+/babA2+ genotype  as  the  positiveample of  vacAs1m1/cagA+/babA2− genotype;  lane  6:  clinical
ample  of  vacAs1m1/cagA−/babA2− genotype;  lane  8:  clinical
ample  of  vacAs1m1/cagA+/babA2+genotype.  Agarose  gel  at
.5%.
terfe
p
p
c
i
o
b
g
r
e
c
(
c
t
c
(
t
g
t
w
p
(
(
p
I
I
t
I
g
7
v
c
g
c
w
D
T
H
l
c
t
r
t
t
T
p
l
M
t
g
q
t
aHelicobacter  pylori  vacA  and  cagA  genotype  diversity  and  in
Detection  of  interferon  gamma  expression
through  immunohistochemistry
The  samples  ﬁxed  in  absolute  alcohol  were  embedded  in
parafﬁn  and  sliced  at  a  thickness  of  3  m.  Each  tissue
section  was  deparafﬁnized  in  xylene  and  rehydrated  with
descending  grades  of  alcohol.  The  slides  were  boiled  in
citrate  buffer  (Declere  1X,  Cell  Marque,  Rocklin,  CA,  USA)
for  20  min  in  an  autoclave  for  antigen  retrieval.  After  per-
meabilization  and  the  blocking  of  endogenous  peroxidase,
the  slices  were  incubated  all  night  with  mouse  anti-human
IFN- monoclonal  antibody  (Santa  Cruz  Biotechnology,  Santa
Cruz,  USA)  at  a  1:50  dilution.  Antibody  binding  was  detected
with  the  Mouse/Rabbit  ImmunoDetector  HRP/DAB  Detec-
tion  System  Kit  (Bio  SB,  Santa  Barbara,  CA,  USA).  The  slices
were  counter-stained  with  hematoxylin  (Biocare  Medical,
Concord,  CA,  USA).  A  total  of  100  mononuclear  cells  were
counted  in  5  randomly  selected  ﬁelds  and  those  with  a
brown  cytoplasmic  or  nuclear  stain  were  considered  posi-
tive.  The  data  were  expressed  as  positive  cell  percentages.
To  validate  the  results  of  the  manual  counting  of  the  IFN-+
cells,  a  random  number  of  samples  equivalent  to  10%  were
selected  and  the  IFN-+ cell  percentage  was  veriﬁed  using
Leica  Microsystems  CMS  GmbH  version  4.3.0  software.
Statistical  analysis
The  frequency  of  the  qualitative  variables,  the  mean  ±
standard  deviation  of  the  parametric  quantitative  variables,
and  median  and  interquartile  range  for  the  nonparametric
variables  were  determined.  The  p  value  was  obtained  with
the  chi-square  test  or  the  Fisher  exact  test  for  qualitative
variables  and  the  Student’s  t  test,  ANOVA,  Mann-Whitney,
or  Kruskal-Wallis  tests  for  quantitative  variables.  Statistical
signiﬁcance  was  set  at  a  p  <  0.05.
Results
Prevalence  of  Helicobacter  pylori  and  vacA/cagA
genotype infection
Ninety-ﬁve  patients  with  conﬁrmed  histologic  diagnosis  of
chronic  gastritis  and  20  with  histopathologic  gastric  ade-
nocarcinoma  results  were  studied.  The  mean  age  for  the
chronic  gastritis  group  was  47.4  years  and  60.9  years  for  the
gastric  cancer  group  (p  <  0.001,  table  1).  Of  the  115  patients
included  in  the  study,  66  (57.4%)  were  H.  pylori-positive  and
vacAs1m1/cagA+ was  the  most  frequent  genotype  at  69.7%
(46/66).  The  prevalence  of  H.  pylori  and  vacA/cagA  geno-
type  infection  varied  between  the  groups  (table  1).
IFN  gamma  expression  in  chronic  gastritis
and in  gastric  cancer
IFN- expression  was  located  predominantly  in  the  cyto-
plasm  of  the  inﬁltrating  mononuclear  cells.  IFN- expression
was  detected  in  the  majority  of  the  H.  pylori-positive
and  H.  pylori-negative  patients  (99/115,  data  not  shown).
No  differences  were  found  in  relation  to  IFN--positive
cells  between  the  patients  with  chronic  gastritis  (median
e
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ercentage  of  positive  cells:  82.6%  in  patients  without  H.
ylori  and  82%  in  infected  persons)  and  those  with  gastric
ancer  (70.5%  in  H.  pylori-negative  patients  and  78.5%  in
nfected  persons)  (ﬁgure  2).  In  chronic  gastritis,  the  median
f  the  percentage  of  IFN--positive  cells  by  age  group  varied
etween  78  and  84%  (interquartile  range  of  70  to  90%);  in
astric  cancer  the  median  was  from  64  to  90%  (interquartile
ange  of  55  to  94%)  and  no  statistically  signiﬁcant  differ-
nces  were  observed  in  the  percentage  of  IFN--positive
ells  in  the  age  groups  of  patients  with  chronic  gastritis
p  =  0.1601)  or  in  the  age  groups  of  patients  with  gastric  can-
er  (p  =  0.1514)  (ﬁgure  3);  nor  were  any  differences  found  in
he  percentage  of  IFN--positive  cells  between  patients  with
hronic  gastritis  and  those  with  gastric  cancer  (p  =  0.8781)
data  not  shown).
IFN-  expression  varied  depending  on  the  H.  pylori  geno-
ype  in  patients  with  chronic  gastritis  and  in  those  with
astric  cancer  (ﬁgure  4).  In  the  chronic  gastritis  group,
hose  infected  with  H.  pylori  vacAs2m2/cagA- presented
ith  a  lower  percentage  of  IFN--positive  cells,  (69%),  com-
ared  with  the  patients  with  H.  pylori  vacAs1m2/cagA-
86.5%),  vacAs1m1/cagA- (86.5%),  and  vacAs1m1/cagA+
82%)  (ﬁgure  5).  Interestingly,  of  5  patients  with  the  H.
ylori  vacAs1m1/cagA+  genotype,  93%  of  the  cells  were
FN--positive  in  4  of  them,  and  96%  in  one  patient.
n  the  patients  with  gastric  cancer  that  were  infected  with
he  vacAs2m2/cagA− genotype,  70.5%  of  the  cells  were
FN--positive;  in  those  infected  with  the  vacAs1m1/cagA-
enotype,  the  percentage  of  IFN--positive  cells  reached
9%;  and  in  the  patients  infected  with  the  H.  pylori
acAs1m1/cagA+ genotype,  the  percentage  of  IFN--positive
ells  was  78%,  reaching  94%  in  one  of  the  7  patients  with  this
enotype  (ﬁgure  5).
There  was  a  variation  between  the  percentage  of  IFN-+
ells  counted  by  microscopic  observation  and  those  veriﬁed
ith  the  Leica  Microsystems  software  of  ±  4.4  cells.
iscussion
he  incidence  and/or  severity  of  the  pathologies  related  to
.  pylori  may  vary  among  geographic  areas31 and  the  preva-
ence  of  infection  and  genotype  distribution  varies  among
ountries,  regions,  and  ethnic  groups.  In  Mexico,  a  varia-
ion  in  the  prevalence  of  H.  pylori  has  been  reported  that
anges  from  86.1%  in  the  southeast,  to  47.1%  in  children  in
he  northeast  of  the  country,  and  to  66%  in  a  population  of
he  Tepehuano  ethnic  group  in  northern  Mexico.32-34 In  2005,
orres  et  al.  reported  that  in  Mexico,  the  prevalence  of  H.
ylori  cagA+  varied  from  47.6%  to  63.4%.35
Nevertheless,  there  are  only  a  few  reports  on  the  preva-
ence  of  infection  from  H.  pylori  and  its  genotypes  in  the
exican  population.  In  this  study,  60%  of  the  cases  of  gas-
ric  cancer  were  H.  pylori-positive,  and  the  vacAs1m1/cagA+
enotype  was  the  most  frequent,  at  58.3%  (7/12).  The  fre-
uency  of  H.  pylori  found  in  our  study  was  the  same  as
hat  reported  by  Morales-Espinosa  et  al.,  but  we  reported
 higher  frequency  than  that  found  in  2008  by  López-Vidal
t  al.  in  a Mexican  population;  they  detected  the  presence
f  H.  pylori  in  38%  of  the  samples  of  patients  with  gastric
ancer.  However,  López-Vidal  et  al.  reported  a  higher  preva-
ence  of  H.  pylori  cagA+  (72%)  than  what  was  found  in  our
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Table  1  Prevalence  of  H.  pylori  and  vacA/cagA  genotype  infection.
Chronic  gastritis  (n  =  95)  Gastric  cancer  (n  =  20)  p  value
Age  (mean  ±  SD;  years)  47.4  ±  16  60.9  ±  16.2  <  0.001a
Sex,  n  (%)
Women  59  (62.1)  11  (55)  0.554b
Men  36  (37.9) 9  (45)
H. pylori,  n  (%)
Negative  41  (43.2) 8  (40) 0.795b
Positive 54  (56.8) 12  (60)
VacA/cagA  genotype,  n  (%)
vacAs2m2/cagA− 3  (5.5)  2  (16.7)  0.587c
vacAs2m2/cagA+ 1  (1.9)  0
vacAs1m2/cagA− 1  (1.9)  0
vacAs1m2/cagA+ 2  (3.7)  0
vacAs1m1/cagA− 8  (14.8)  3  (25)
vacAs1m1/cagA+ 39  (72.2)  7  (58.3)
Total 54  (100)  12  (100)
a Student’s t test;
b
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*Chi-square test;
c Fisher exact test.
tudy  on  patients  from  the  State  of  Guerrero  with  gastric
ancer  (58%).  These  differences  may  be  due  to  the  different
eographical  regions  the  patients  come  from.  H.  pylori  geno-
ypes  have  been  reported  to  circulate  differentially  between
opulations  and  geographic  zones.  In  a  Northeastern  Brazil-
an  population  in  2012,  Figueiredo  Cavalcante  et  al.  found
hat  83.3%  of  the  H.  pylori  strains  were  vacAs1, 53.3%  were
acAm1,  and  96.7%  were  cagA+  in  patients  with  gastric
ancer.25-28
Furthermore,  we  found  that  in  the  cases  of  chronic  gas-
ritis,  56.8%  were  H.  pylori-positive  and  the  most  frequent
enotypes  were  vacAs1m1,  with  87%,  and  cagA+,  with  77.8%.
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igure  2  IFN-  expression  in  patients  with  chronic  gastritis  and  pa
 Mann-Whitney  test.he  frequency  of  the  vacAs1m1  genotype  in  our  study  was
igher  than  the  43.4%  reported  by  Román-Román  et  al.  in
013  on  a  population  from  the  State  of  Guerrero  with  chronic
astritis,  and  it  was  also  higher  than  that  found  by  Paniagua
t  al.  in  2009  in  patients  from  the  State  of  Mexico;  they
eported  that  of  the  patients  with  chronic  gastritis  that  were
.  pylori-positive  (60.1%),  40%  of  them  had  the  vacAs1m1
enotype  and  52%  were  cagA+. In  2012,  Figueiredo  Caval-
ante  et  al.  found  that  the  s1  and  m1  allelotypes  were  the
ost  frequent  in  patients  with  chronic  gastritis  at  72.4%  and
1.3%,  respectively,  and  that  73.7%  were  H.  pylori  cagA+;
n  2009,  Torres  et  al.  found  a  frequency  of  54.9%  for  the
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Helicobacter  pylori  vacA  and  cagA  genotype  diversity  and  interferon  gamma  expression  225
<20 years
*P=0.1601
82%
78%
83% 84%
91%
78%
64%
*P=0.1514
10
0
80
60
40
De 20 a 39
years
Chronic gastritis Gastric cancer
De 40 a 59
years
≥60 years <20 years De 20 a 39
years
De 40 a 59
years
≥60 a years
Pe
rc
en
ta
ge
 o
f I
FN
-γ-
po
sit
ive
 c
el
ls
hron
t
i
p
t
d
l
m
t
rFigure  3  Percentage  of  IFN--positive  cells  in  patients  with  c
* Kruskal-Wallis  test.
vacAs1m1  genotype  and  70.6%  for  the  cagA+ genotype  in
Cuban  patients  with  functional  dyspepsia.  In  our  study,  vacA
and  cagA  genotype  detection  was  carried  out  with  the  same
starters  used  by  Torres  et  al.,  and  in  both  studies  the  H.
pylori  DNA  and  its  genotypes  were  determined  from  the  total
DNA  from  the  gastric  biopsy.  Thus,  the  discrepancies  in  the
frequencies  can  probably  be  explained  by  the  differences
in  the  population  origins,  the  number  of  patients,  and  the
diagnostic  criteria  employed,  and  perhaps  by  the  differences
in  methodology  for  collecting  and  processing  the  biopsies,
as  well.28-31 The  probability  of  detecting  H.  pylori  DNA  is
inﬂuenced  by  the  number  of  bacteria  in  the  tissue  used  as
t
w
vacAs2m2/cagA– vacAs1m1/cagA–
Figure  4  Immunohistochemistry  of  IFN-  expression  in  gastric  bi
gastric cancer,  counterstained  with  hematoxylin  (x10).  A1-A4)  Gast
biopsies from  patients  with  gastric  cancer.  B4)  Amygdala  biopsy,  negic  gastritis  or  with  gastric  cancer,  distributed  by  age  groups.
he  genomic  DNA  source.  The  oligonucleotides  employed
n  the  PCR  used  in  the  present  study  for  revealing  the  H.
ylori  16S  rRNA  gene  enabled  the  detection  of  2.5  ng  of
he  H.  pylori  DNA  in  50  or  150  ng  of  human  DNA  and  the
istinction  between  the  H.  pylori  16S  rRNA  gene  and  Campy-
obacter  spp.  and  the  other  isolated  bacteria  in  the  gastric
ucosa.29 The  use  of  multiplex  PCR  enabled  the  collection  of
he  bacterial  genotype  in  a shorter  period  of  time,  a  reduced
eagent  expense,  and  more  opportune  delivery  of  the  results
o  the  patients.
In  this  study,  we  compared  IFN- expression  in  patients
ith  chronic  gastritis  and  patients  with  gastric  cancer  that
vacAs1m1/cagA+ H. pylori –/ IFN -γ negative
opsies  from  patients  with  chronic  gastritis  and  patients  with
ric  biopsies  of  patients  with  chronic  gastritis.  B1-B3)  Gastric
ative  reaction  control  (the  primary  antibody  was  omitted).
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Figure  5  IFN-  expression  by  H.  pylori  genotype  in  samples  from  patients  with  chronic  gastritis  and  patients  with  gastric  cancer.
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H Kruskal-Wallis  test.
ere  either  infected  or  not  with  H.  pylori; we  also  com-
ared  the  patients  by  different  age  groups  and  by  groups
nfected  with  different  bacterial  genotypes.  We  found  that
6.1%  of  the  samples  were  IFN--positive  and  despite  the
act  that  there  were  no  differences  between  IFN- expres-
ion  and  H.  pylori  infection  in  the  two  study  groups,  our
nalysis  revealed  lower  IFN- expression  in  the  gastric  can-
er  group  than  in  the  chronic  gastritis  group,  regardless  of
.  pylori  infection.  In  contrast,  in  2005  Lopes  et  al.,  in  sam-
les  from  Portuguese  children  and  adolescents,  and  in  1998,
indholm  et  al.,  in  Swedish  patients,  reported  that  IFN-
xpression  was  higher  in  the  samples  of  patients  that  were
.  pylori-positive.9,13 Taking  into  consideration  that  chronic
astritis  is  an  inﬂammatory  process  of  varying  magnitude
hat  can  give  rise  to  gastric  adenocarcinoma  within  a  10
o  15-year  period  of  progression  and  that  the  intensity  of
he  immune  response  undergoes  changes  as  individuals  get
lder,  the  number  of  cells  with  positive  IFN- staining  was
nalyzed  with  respect  to  patient  age.  The  lack  of  statisti-
ally  signiﬁcant  differences  in  regard  to  age  may  be  related
o  the  diversity  and  intensity  of  the  inﬂammatory  stimuli
eriving  from  H.  pylori, along  with  other  factors  related  to
atient  lifestyle  and  the  presence  of  other  infectious  agents
uch  as  the  Epstein-Barr  virus.
Through  our  analysis  of  IFN- expression,  in  accor-
ance  with  the  H.  pylori  vacA/cagA  genotype,  we  found
hat  the  percentage  of  cells  expressing  the  cytokine  was
ower  in  both  groups  when  the  subjects  were  infected
ith  the  less  virulent  genotype  (vacAs2m2/cagA+),  69%
n  the  gastritis  patients  and  70.5%  in  the  gastric  cancer
atients;  in  the  gastritis  group  there  was  higher  IFN-
xpression  (86.5%)  in  the  H.  pylori-positive  vacAs1m2/cagA+
nd  vacAs1m1/cagA- patients;  in  the  gastric  cancer  group
here  was  a  decrease  in  expression  to  79  and  78%  in
w
t
e
p.  pylori-positive  vacAs1m1/cagA-  and  vacAs1m1/cagA+
atients,  respectively.  Similar  ﬁndings  were  reported  by
ang  et  al.  in  2007  in  a  Chinese  population;  they  found  that
here  was  a  reduction  in  IFN- expression  in  patients  with
hronic  gastritis  and  gastric  cancer,  infected  with  H.  pylori
agA+,  that  occurred  as  the  gastric  lesion  became  more
evere.16 In  patients  with  chronic  gastritis,  the  increased
FN- levels  could  contribute  to  gastric  inﬂammation  due  to
ononuclear  phagocytic  activation  and  to  over-regulation
f  MHC-class  I  and  class  II  molecular  expression.13 In  addi-
ion  to  playing  an  important  role  in  the  antitumor  response,
FN-  has  also  been  reported  to  possibly  have  tumori-
enic  effects.36 In  2009,  Sayi  et  al.  reported  that,  in  a
urine  model,  IFN- produced  by  CD4+  T  cells  played  an
mportant  role  in  H.  pylori  infection  control  but,  on  the
ther  hand,  induced  pre-neoplastic  changes  in  the  gastric
ucosa.11 High  IFN- expression  in  the  group  of  patients
ith  gastric  cancer  can  have  different  signiﬁcations:  a)  it
ould  be  a  good  outcome  factor,  in  accordance  with  the
eports  that  IFN- can  promote  the  elimination  of  neo-
lastic  cells  through  its  angiostatic  action  that  restricts
umor  growth  by  interfering  with  the  blood  supply,15 and
)  it  could  be  exerting  a  pro-tumor  effect  through  pro-
iferative  and  anti-apoptotic  signals,  and  facilitating  the
scape  of  tumor  cells  from  the  cytolytic  action  of  the  NK
ells  and  cytotoxic  T  lymphocytes.36 Patient  follow-up  is
ecessary  in  order  to  verify  the  signiﬁcance  of  our  ﬁnd-
ngs.
In  conclusion,  IFN- expression  varies  depending  on  the
.  pylori  vacA  and  cagA  genotype,  but  not  in  accordance
ith  the  presence  of  chronic  gastritis  or  gastric  cancer.  Fur-
her  studies  are  needed  in  order  to  determine  whether  IFN-
xpression  could  be  a  useful  biomarker  in  gastric  cancer
rognosis.
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